Literature DB >> 7734193

Sequential determination of viral load and phenotype in human immunodeficiency virus type 1 infection.

E S Daar1, T Chernyavskiy, J Q Zhao, P Krogstad, I S Chen, J A Zack.   

Abstract

Detailed studies of HIV viral load and phenotype were performed on sequentially cryopreserved peripheral blood mononuclear cells (PBMCs) from eight infected individuals followed in the Los Angeles Multicenter AIDS Cohort Study. Three individuals remained clinically and immunologically stable over a 5- to 8-year period, three demonstrated precipitous and two gradual declines in CD4+ T lymphocytes. Viral load in PBMCs was quantitated by limiting dilution culture and DNA PCR, while minimally passaged viral isolates were studied for their ability to induce syncytium formation in vitro and, when relevant, sensitivity to zidovudine (ZDV). Viral burden remained relatively low in those who remained clinically and immunologically stable, while increasing substantially in all five individuals who experienced a decline in CD4+ T lymphocytes. Two subjects were noted to have a switch from non-syncytium-inducing (NSI) to syncytium-inducing (SI) isolates immediately preceding a precipitous decline in CD4+ T lymphocytes, while the third individual who experienced such a decline and the two who had gradual declines did not develop SI isolates. Moreover, of the three subjects who experienced a decrease in CD4+ T lymphocyte number and were given ZDV during the study period, none were noted to develop resistance to this agent. In summary, the virology in clinically and immunologically stable individuals was characterized by relatively low viral burden in PBMCs and a predominance of NSI isolates.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7734193     DOI: 10.1089/aid.1995.11.3

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  7 in total

1.  Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals.

Authors:  G Sanchez; X Xu; J C Chermann; I Hirsch
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

2.  Syncytium induction in primary CD4+ T-cell lines from normal donors by human immunodeficiency virus type 1 isolates with non-syncytium-inducing genotype and phenotype in MT-2 cells.

Authors:  B J Todd; P Kedar; J H Pope
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

3.  Determinant in human immunodeficiency virus type 1 for efficient replication under cytokine-induced CD4(+) T-helper 1 (Th1)- and Th2-type conditions.

Authors:  Y Suzuki; Y Koyanagi; Y Tanaka; T Murakami; N Misawa; N Maeda; T Kimura; H Shida; J A Hoxie; W A O'Brien; N Yamamoto
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

4.  In vivo pathogenic properties of two clonal human immunodeficiency virus type 1 isolates.

Authors:  B D Jamieson; S Pang; G M Aldrovandi; J Zha; J A Zack
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

5.  Relationship between HIV coreceptor tropism and disease progression in persons with untreated chronic HIV infection.

Authors:  Matthew Bidwell Goetz; Robert Leduc; Jay R Kostman; Ann M Labriola; Yolanda Lie; Jodi Weidler; Eoin Coakley; Michael Bates; Roberta Luskin-Hawk
Journal:  J Acquir Immune Defic Syndr       Date:  2009-03-01       Impact factor: 3.731

6.  A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor.

Authors:  B J Doranz; K Grovit-Ferbas; M P Sharron; S H Mao; M B Goetz; E S Daar; R W Doms; W A O'Brien
Journal:  J Exp Med       Date:  1997-10-20       Impact factor: 14.307

7.  Cell activation and HIV-1 replication in unstimulated CD4+ T lymphocytes ingesting exosomes from cells expressing defective HIV-1.

Authors:  Claudia Arenaccio; Chiara Chiozzini; Sandra Columba-Cabezas; Francesco Manfredi; Maurizio Federico
Journal:  Retrovirology       Date:  2014-06-12       Impact factor: 4.602

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.